Zacks: Brokerages Anticipate Zai Lab Limited (NASDAQ:ZLAB) Will Announce Earnings of -$0.94 Per Share

Wall Street brokerages predict that Zai Lab Limited (NASDAQ:ZLABGet Rating) will announce earnings of ($0.94) per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Zai Lab’s earnings. The lowest EPS estimate is ($1.01) and the highest is ($0.90). Zai Lab posted earnings per share of ($1.76) during the same quarter last year, which indicates a positive year-over-year growth rate of 46.6%. The business is scheduled to announce its next earnings report on Monday, January 1st.

On average, analysts expect that Zai Lab will report full-year earnings of ($4.18) per share for the current fiscal year, with EPS estimates ranging from ($5.33) to ($3.55). For the next fiscal year, analysts forecast that the business will post earnings of ($2.92) per share, with EPS estimates ranging from ($4.04) to ($1.10). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow Zai Lab.

Zai Lab (NASDAQ:ZLABGet Rating) last posted its quarterly earnings results on Tuesday, March 1st. The company reported ($2.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.66) by ($0.58). Zai Lab had a negative net margin of 324.08% and a negative return on equity of 37.26%. The business had revenue of $44.17 million during the quarter, compared to the consensus estimate of $54.78 million.

ZLAB has been the topic of several research analyst reports. JPMorgan Chase & Co. reduced their price objective on Zai Lab from $136.00 to $112.00 and set an “overweight” rating on the stock in a research note on Monday, April 4th. SVB Leerink dropped their target price on Zai Lab from $102.00 to $101.00 and set an “outperform” rating for the company in a research report on Thursday, April 21st. Citigroup dropped their target price on Zai Lab from $198.00 to $193.00 in a research report on Thursday, May 12th. Zacks Investment Research upgraded Zai Lab from a “sell” rating to a “hold” rating in a research report on Thursday, April 7th. Finally, Macquarie began coverage on Zai Lab in a research report on Friday, January 21st. They set an “outperform” rating and a $64.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $117.50.

ZLAB opened at $35.72 on Tuesday. The stock’s fifty day simple moving average is $39.58 and its 200 day simple moving average is $54.48. Zai Lab has a 1-year low of $24.50 and a 1-year high of $181.92. The stock has a market cap of $3.50 billion, a PE ratio of -6.09 and a beta of 1.20.

A number of institutional investors have recently bought and sold shares of the stock. CWM LLC bought a new stake in shares of Zai Lab in the 4th quarter valued at about $35,000. Parallel Advisors LLC grew its stake in shares of Zai Lab by 97.9% in the 4th quarter. Parallel Advisors LLC now owns 673 shares of the company’s stock worth $42,000 after buying an additional 333 shares during the last quarter. Quadrant Capital Group LLC grew its stake in shares of Zai Lab by 50.9% in the 4th quarter. Quadrant Capital Group LLC now owns 1,198 shares of the company’s stock worth $75,000 after buying an additional 404 shares during the last quarter. Penserra Capital Management LLC boosted its stake in Zai Lab by 13.6% during the 3rd quarter. Penserra Capital Management LLC now owns 1,585 shares of the company’s stock valued at $167,000 after purchasing an additional 190 shares during the last quarter. Finally, HighTower Advisors LLC purchased a new stake in Zai Lab during the 3rd quarter valued at $203,000. Institutional investors and hedge funds own 72.65% of the company’s stock.

About Zai Lab (Get Rating)

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors.

Read More

Get a free copy of the Zacks research report on Zai Lab (ZLAB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Zai Lab (NASDAQ:ZLAB)

Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.